home / stock / mbio / mbio quote
Last: | $0.3161 |
---|---|
Change Percent: | -2.97% |
Open: | $0.3608 |
Close: | $0.3161 |
High: | $0.3699 |
Low: | $0.315 |
Volume: | 253,463 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.3161 | $0.3608 | $0.3161 | $0.3699 | $0.315 | 253,463 | 04-26-2024 |
$0.3504 | $0.3637 | $0.3504 | $0.3697 | $0.32 | 63,966 | 04-25-2024 |
$0.3501 | $0.35 | $0.3501 | $0.364899 | $0.3303 | 123,283 | 04-24-2024 |
$0.3597 | $0.35 | $0.3597 | $0.3697 | $0.3311 | 122,956 | 04-23-2024 |
$0.34 | $0.369 | $0.34 | $0.3985 | $0.3313 | 313,025 | 04-22-2024 |
$0.3416 | $0.3601 | $0.3416 | $0.3999 | $0.3411 | 138,048 | 04-19-2024 |
$0.371 | $0.385 | $0.371 | $0.45 | $0.3701 | 211,111 | 04-18-2024 |
$0.384 | $0.3849 | $0.384 | $0.3849 | $0.3333 | 454,098 | 04-17-2024 |
$0.3462 | $0.37 | $0.3462 | $0.3997 | $0.339 | 364,984 | 04-16-2024 |
$0.375 | $0.52 | $0.375 | $0.52 | $0.33 | 705,665 | 04-15-2024 |
$0.508 | $0.5308 | $0.508 | $0.5498 | $0.508 | 146,725 | 04-12-2024 |
$0.5472 | $0.545 | $0.5472 | $0.55 | $0.5196 | 184,694 | 04-11-2024 |
$0.5196 | $0.66 | $0.5196 | $0.689 | $0.51 | 1,059,032 | 04-10-2024 |
$0.676 | $0.719 | $0.676 | $0.733499 | $0.6475 | 129,760 | 04-09-2024 |
$0.6985 | $0.7519 | $0.6985 | $0.812 | $0.66 | 328,445 | 04-08-2024 |
$0.7626 | $0.809 | $0.7626 | $0.8199 | $0.757 | 58,984 | 04-05-2024 |
$0.785 | $0.861 | $0.785 | $0.861 | $0.7462 | 240,428 | 04-04-2024 |
$0.82 | $0.9616 | $0.82 | $1.02 | $0.81 | 469,422 | 04-03-2024 |
$1.02 | $1.07 | $1.02 | $1.07 | $0.9501 | 48,324 | 04-02-2024 |
$1.05 | $1.05 | $1.05 | $1.06 | $0.98 | 62,965 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong founda...
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures fo...